Comment on “Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)”
Diabetes, Obesity and Metabolism, EarlyView.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Patrick B.
Ryan
PhD
,
Norm
Rosenthal
MD Source Type: research
More News: Canagliflozin | Cardiology | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Heart | Heart Failure | Invokana | Obesity | SGLT2 Inhibitors